Ori Ben-Yehuda

Executive Director, Clinical Trials Center at Cardiovascular Research Foundation

Ori Ben-Yehuda

Ori Ben-Yehuda

Executive Director, Clinical Trials Center at Cardiovascular Research Foundation

Overview
Career Highlights

Cardiovascular Research Foundation

RelSci Relationships

88

Number of Boards

1

Relationships
RelSci Relationships are individuals Ori Ben-Yehuda likely has professional access to. A relationship does not necessarily indicate a personal connection.

Director & Co-Founder at Cardiovascular Research Foundation

Relationship likelihood: Strong

Executive Director & Chief Scientific Officer at Cardiovascular Research Foundation

Relationship likelihood: Strong

Former President, Chief Executive Officer & Director at Cardiovascular Research Foundation

Relationship likelihood: Strong

Former Chief Executive Officer & President at Cardiovascular Research Foundation

Relationship likelihood: Strong

Director-Interventional Cardiology at Stanford Health Care

Relationship likelihood: Strong

Director, Cardiovascular Interventions at New York Presbyterian Hospital

Relationship likelihood: Strong

Director at Adenosine Therapeutics LLC

Relationship likelihood: Strong

Various Designation at Johnson & Johnson

Relationship likelihood: Strong

Former President at Cardiovascular Research Foundation

Relationship likelihood: Strong

Professor of Medicine & Judith & Jack White Chair in Cardiology, Division of Cardiovascular Medicine at University of California San Diego - School of Medicine

Relationship likelihood: Strong

Paths to Ori Ben-Yehuda
Potential Connections via
Relationship Science
You
Ori Ben-Yehuda
Executive Director, Clinical Trials Center at Cardiovascular Research Foundation
Career History
Executive Director, Clinical Trials Center
Current

CARDIOVASCULAR RESEARCH FOUNDATION IS AN INDEPENDENT, ACADEMICALLY FOCUSED ORGANIZATION DEDICATED TO IMPROVING THE SURVIVAL AND QUALITY OF LIFE FOR PEOPLE WITH CARDIOVASCULAR DISEASE THROUGH RESEARCH AND EDUCATION. THE ORGANIZATION HAS PLAYED A MAJOR ROLE IN REALIZING DRAMATIC IMPROVEMENTS IN THE LIVES OF COUNTLESS NUMBERS OF PATIENTS BY ESTABLISHING THE SAFE USE OF NEW TECHNOLOGIES AND THERAPIES IN THE SUBSPECIALTY OF INTERVENTIONAL CARDIOLOGY AND ENDOVASCULAR MEDICINE.

Chief Medical Officer
2018 - ?

CardioVascular BioTherapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.

Boards & Committees
Co-Chair, Advisory Board
Current

Israel China Biotechnology (ICB) Ltd. engages in investments in biomedical companies and in research and development of equipment for diagnosing heart diseases. It operates through the Electrocardiogram segment and the Investments segment. The Electrocardiogram segment engages in the development, manufacture, and marketing of technologies and systems for diagnosing ischemic heart diseases. The Investments segment engages in investments in medical companies. The company was founded on November 15, 1999 and is headquartered in Tel Aviv, Israel.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ori Ben-Yehuda. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ori Ben-Yehuda's profile does not indicate a business or promotional relationship of any kind between RelSci and Ori Ben-Yehuda.